Rubicon Healthcare Partners is a growth-oriented investment firm focused on Nordic life science companies supplying products, services, and technologies to the healthcare and biopharmaceutical industries. Through this partnership, Rubicon brings valuable experience and networks to support PeptiSystems’ international expansion and strategic development, the company states. Rubicon will become the largest shareholder in PeptiSystems after the transaction.

“We were attracted to PeptiSystems’ innovative best-in-class instrument portfolio, customer-centric approach, and excellent management team,” says Ole J. Dahlberg, Managing Partner at Rubicon Healthcare Partners.

Commercial development

The investment enables PeptiSystems to further accelerate its commercial development and strengthen the organization for the next phase of growth. Building on its expanding customer base and the commercial momentum, the company is now advancing toward large-scale industrial applications and supporting customers in the transition to GMP production of therapeutic peptides and oligonucleotides.

“Rubicon Healthcare Partners’s global life science experience and Nordic presence will be a valuable asset as we take the next steps in driving commercialization and scale our technology for industrial applications. This investment reflects confidence in our team and our strategy to drive growth in a rapidly expanding market,” says Karin Granath, CEO of PeptiSystems.

The transaction is subject to customary closing conditions, including review under Sweden’s Foreign Direct Investment screening legislation.